A cross-sectional study revealed that MASLD patients exhibit lower adiponectin levels, higher serum leptin levels, and an increased leptin-to-adiponectin (L/A) ratio. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.